CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 87 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $94,920,000 | +38.3% | 17,875,655 | 0.0% | 9.39% | +93.4% |
| Q2 2019 | $68,643,000 | -24.7% | 17,875,655 | 0.0% | 4.86% | -15.6% |
| Q1 2019 | $91,166,000 | +405.0% | 17,875,655 | +90.1% | 5.76% | +333.4% |
| Q4 2018 | $18,052,000 | -21.0% | 9,402,317 | +55.5% | 1.33% | +8.0% |
| Q3 2018 | $22,849,000 | +21.2% | 6,044,719 | 0.0% | 1.23% | +1.1% |
| Q2 2018 | $18,860,000 | +58.0% | 6,044,719 | +21.0% | 1.22% | +11.5% |
| Q1 2018 | $11,937,000 | -31.8% | 4,994,719 | +11.6% | 1.09% | -30.9% |
| Q4 2017 | $17,492,000 | +1778.8% | 4,473,607 | +1111.4% | 1.58% | +1434.0% |
| Q3 2017 | $931,000 | -86.8% | 369,298 | -87.2% | 0.10% | -89.1% |
| Q4 2015 | $7,078,000 | -59.3% | 2,888,942 | -50.2% | 0.95% | -61.2% |
| Q3 2015 | $17,409,000 | -23.6% | 5,802,885 | +5.2% | 2.45% | +6.9% |
| Q2 2015 | $22,789,000 | +8.5% | 5,517,885 | +13.8% | 2.29% | +19.8% |
| Q1 2015 | $21,000,000 | – | 4,849,870 | – | 1.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 17,875,655 | $94,920,000 | 9.39% |
| TANAKA CAPITAL MANAGEMENT INC | 283,334 | $1,505,000 | 4.86% |
| GABLES CAPITAL MANAGEMENT INC. | 490,564 | $2,606,000 | 1.84% |
| MANGROVE PARTNERS IM, LLC | 2,508,838 | $13,322,000 | 1.61% |
| Broadfin Capital, LLC | 880,303 | $4,674,000 | 0.86% |
| Atom Investors LP | 1,012,355 | $5,376,000 | 0.37% |
| Capital Impact Advisors, LLC | 179,868 | $948,000 | 0.36% |
| KNOTT DAVID M | 151,415 | $804,000 | 0.34% |
| EMERALD ADVISERS, LLC | 1,175,958 | $6,244,000 | 0.29% |
| CADENCE CAPITAL MANAGEMENT LLC | 371,075 | $1,970,000 | 0.28% |